Takeda (TAK) tops the buyer rankings as navenibart directly threatens its Takhzyro franchise; AstraZeneca (AZN) ranks second through its Alexion rare-disease platform. BioCryst hit its first full year of profitability in 2025, with Q2 2026 revenue up 34% to $218 million, fueling acquisition speculation. BioCryst Pharmaceuticals (NASDAQ:BCRX) closed at $9.84 on August 10, 2026, giving the Durham-based rare-disease specialist a market cap of roughly $2.5 billion. Notably, BioCryst is itself an acquirer, having closed the Astria Therapeutics deal on January 23, 2026, to bring in navenibart. BioCryst screens well for a take-private: recurring Orladeyo cash flow, 45.1% operating margin, and a manageable $2.40 billion equity check.